Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Price Sensitive Information

30 Apr 2009 12:55

RNS Number : 4931R
Beximco Pharmaceuticals Ltd
30 April 2009
 



BEXIMCO PHARMACEUTICALS LTD.

30th April, 2009

PRICE SENSITIVE INFORMATION

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors in their meeting held on 30th April, 2009 at 5.00 p.m. has decided the following: 

1. Revaluation of Assets of the Company: 

Accepted an independent report on the valuation of

Lands, Buildings, Plant and Machinery as of 31 December, 2008 issued by M/S S F Ahmed & Co. Chartered Accountants and Valuer showing an aggregate depreciated current cost of Tk 5,485,286,356 resulting in a revaluations surplus aggregating Tk 1,711,174,747

 

2. Date & Time of 33rd AGM of the: 

Company for the year 2008

 

16th June, 2009 at 9.30 a.m

3. Proposed Dividend:

10% Cash and 20% Stock dividend 

for the year ended 31 December 2008

 

4. Record date:

25th May, 2009.

 

5. Venue of AGM:

1 Shahbag C/A, DhakaBangladesh

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

MD. ASAD ULLAH, FCS, Company Secretary

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFBLFXKZBEBBX
Date   Source Headline
30th Jan 20237:00 amRNSHalf Year Results 2022-23
19th Jan 20237:00 amRNSPayment of Cash Dividend
23rd Dec 20227:00 amRNSAnnual General Meeting Statement
29th Nov 20222:06 pmRNSSecond Price Monitoring Extn
29th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSAGM Notification
11th Nov 20227:00 amRNSFinancial Results for the First Quarter
8th Nov 20227:00 amRNSResults for the 12-month period ended 30 June 2022
28th Oct 20227:00 amRNSNotification of Preliminary Results and AGM
28th Apr 20227:00 amRNSQ3 Financial Results
1st Apr 20227:00 amRNSSanofi Bangladesh Ltd. renamed Synovia Pharma PLC
17th Mar 20222:30 pmRNSMPP sub-license for Pfizer’s COVID-19 treatment
28th Jan 20227:00 amRNSHalf Year Results 2021-22
21st Jan 20227:00 amRNSPayment of Cash Dividend
20th Jan 20229:00 amRNSLicense to produce molnupiravir for COVID-19
30th Dec 202110:38 amRNSWorld's first generic version of Pfizer’s Paxlovid
24th Dec 20217:00 amRNSAnnual General Meeting Statement
8th Dec 20217:00 amRNSDelivery of COVID-19 vaccine doses
2nd Dec 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Nov 20217:43 amRNSStatement re: media comment
16th Nov 20217:00 amRNSNotice of AGM
11th Nov 202110:30 amRNSResults for First Quarter Ended 30 September 2021
9th Nov 20217:00 amRNSLaunch of world’s first generic molnupiravir
2nd Nov 20217:00 amRNSResults for the year ended 30 June 2021
21st Oct 202112:36 pmRNSNotification of Preliminary Results and AGM
11th Oct 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
1st Oct 20217:00 amRNSCompletion of Sanofi Bangladesh Acquisition
14th Sep 202110:20 amRNSSanofi Bangladesh Share Purchase Agreement signed
3rd Sep 20211:10 pmRNSAcquisition Approved by Bangladesh Bank
25th Aug 20216:01 pmRNSStatement re: media comment
26th Jul 20217:00 amRNSFDA approval for muscle relaxant drug Baclofen
7th Jul 20212:23 pmRNSUpdate on the supply of COVID-19 vaccine
30th Apr 20217:00 amRNSQ3 Financial Results
28th Apr 20217:00 amRNSUpdate on the supply of COVID-19 vaccine
24th Mar 20214:41 pmRNSSecond Price Monitoring Extn
24th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20212:06 pmRNSSecond Price Monitoring Extn
24th Mar 20212:00 pmRNSPrice Monitoring Extension
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
4th Feb 20217:34 amRNSUpdate on the supply of COVID-19 vaccine
28th Jan 20217:00 amRNSHalf Year Results 2020-21
22nd Jan 20217:00 amRNSPayment of Cash Dividend
21st Jan 20219:34 amRNSProposed acquisition of stake in Sanofi Bangladesh
18th Jan 20217:00 amRNSBoard Changes
14th Jan 20219:00 amRNSUpdate on the supply of COVID-19 vaccine
11th Jan 20217:00 amRNSStock Dividend Issued
11th Jan 20217:00 amRNSConfirmation of Board Changes
21st Dec 20207:00 amRNSAGM Statement
2nd Dec 202011:01 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.